133 related articles for article (PubMed ID: 11706114)
21. Hemolytic anemia associated with intravenous immunoglobulin.
Wilson JR; Bhoopalam H; Fisher M
Muscle Nerve; 1997 Sep; 20(9):1142-5. PubMed ID: 9270670
[TBL] [Abstract][Full Text] [Related]
22. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
23. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Barsheshet A; Marai I; Appel S; Zimlichman E
Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
[TBL] [Abstract][Full Text] [Related]
24. Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience.
Sarti L; Falai T; Pinto F; Tendi E; Matà S
Neurol Sci; 2009 Jun; 30(3):213-8. PubMed ID: 19259617
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin: adverse effects and safe administration.
Orbach H; Katz U; Sherer Y; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
[TBL] [Abstract][Full Text] [Related]
26. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies.
Brannagan TH
Neurology; 2002 Dec; 59(12 Suppl 6):S33-40. PubMed ID: 12499469
[TBL] [Abstract][Full Text] [Related]
27. Complications of intravenous gammaglobulin in neuromuscular and other diseases.
Bertorini TE; Nance AM; Horner LH; Greene W; Gelfand MS; Jaster JH
Muscle Nerve; 1996 Mar; 19(3):388-91. PubMed ID: 8606709
[No Abstract] [Full Text] [Related]
28. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.
Dobloug C; Walle-Hansen R; Gran JT; Molberg Ø
Clin Exp Rheumatol; 2012; 30(6):838-42. PubMed ID: 22935197
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
30. Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise?
Perazella MA; Cayco AV
Am J Ther; 1998 Nov; 5(6):399-403. PubMed ID: 10099084
[TBL] [Abstract][Full Text] [Related]
31. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Patwa HS; Chaudhry V; Katzberg H; Rae-Grant AD; So YT
Neurology; 2012 Mar; 78(13):1009-15. PubMed ID: 22454268
[TBL] [Abstract][Full Text] [Related]
32. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study.
Ramírez E; Romero-Garrido JA; López-Granados E; Borobia AM; Pérez T; Medrano N; Rueda C; Tong HY; Herrero A; Frías J
Thromb Res; 2014 Jun; 133(6):1045-51. PubMed ID: 24731561
[TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
34. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
[TBL] [Abstract][Full Text] [Related]
35. [Intravenous IgG for treatment of neuromuscular diseases].
Vedeler CA; Mellgren SI; Omdal R; Torbergsen T; Aasly J
Tidsskr Nor Laegeforen; 2010 Sep; 130(17):1717-20. PubMed ID: 20835282
[TBL] [Abstract][Full Text] [Related]
36. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases.
Koffman BM; Dalakas MC
Muscle Nerve; 1997 Sep; 20(9):1102-7. PubMed ID: 9270664
[TBL] [Abstract][Full Text] [Related]
37. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
38. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
39. A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration Rates.
Bauer S; Fadeyi M; Chan S
J Infus Nurs; 2019; 42(6):297-302. PubMed ID: 31693563
[TBL] [Abstract][Full Text] [Related]
40. Role of intravenous immunoglobulin in the treatment of Kawasaki disease.
Lo MS; Newburger JW
Int J Rheum Dis; 2018 Jan; 21(1):64-69. PubMed ID: 29205910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
